Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -34.50% is 138% below its 5-year average of -14.50%, near the high end of its 5-year range (-958.21%–178.66%).
As of the fiscal period ended Tuesday, June 30, 2026. 261.39% below its 12-month average of 21.37%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -34.50%.
RETURN ON EQUITY (ROE)
-34.50%
RETURN ON EQUITY (ROE) AVG TTM
21.37%
RETURN ON EQUITY (ROE) AVG 3Y
44.05%
RETURN ON EQUITY (ROE) AVG 5Y
-14.50%
RETURN ON EQUITY (ROE) AVG 10Y
-95.19%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-261.39%
CURRENT VS 3Y AVG
-178.32%
CURRENT VS 5Y AVG
-137.84%
CURRENT VS 10Y AVG
+63.76%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+17.89%
vs the sector median at left
PAVmed Inc.
Market Cap
$17.52M
Return on Equity (ROE)
-34.50%
TTM Avg
21.37%
3Y Avg
44.05%
5Y Avg
-14.50%
Market Cap
$17.11M
Return on Equity (ROE)
-54.45%
TTM Avg
-33.23%
3Y Avg
-44.23%
5Y Avg
-52.50%
Market Cap
$17.37M
Return on Equity (ROE)
-71.57%
TTM Avg
-65.12%
3Y Avg
-85.39%
5Y Avg
-90.29%
Market Cap
$16.81M
Return on Equity (ROE)
-125.30%
TTM Avg
118.50%
3Y Avg
7030.24%
5Y Avg
4638.47%
Market Cap
$16.70M
Return on Equity (ROE)
N/A
TTM Avg
-416.37%
3Y Avg
-259.03%
5Y Avg
-190.00%
Market Cap
$16.70M
Return on Equity (ROE)
-101.76%
TTM Avg
-188.04%
3Y Avg
-167.76%
5Y Avg
-134.95%
Market Cap
$16.62M
Return on Equity (ROE)
-170.55%
TTM Avg
-79.16%
3Y Avg
-71.01%
5Y Avg
-42.13%
Market Cap
$17.99M
Return on Equity (ROE)
N/A
TTM Avg
-3014.83%
3Y Avg
-1589.49%
5Y Avg
-1032.64%
Market Cap
$18.04M
Return on Equity (ROE)
-117.98%
TTM Avg
-84.94%
3Y Avg
-64.05%
5Y Avg
-76.29%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PAVmed Inc. (PAVM) | $17.52M | -34.50% | 21.37% | 44.05% | -14.50% |
| Lipocine Inc. (LPCN)vs › | $17.11M | -54.45% | -33.23% | -44.23% | -52.50% |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.37M | -71.57% | -65.12% | -85.39% | -90.29% |
| Palatin Technologies, Inc. (PTN)vs › | $16.81M | -125.30% | 118.50% | 7030.24% | 4638.47% |
| Dyadic International, Inc. (DYAI)vs › | $16.70M | N/A | -416.37% | -259.03% | -190.00% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.70M | -101.76% | -188.04% | -167.76% | -134.95% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.62M | -170.55% | -79.16% | -71.01% | -42.13% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.99M | N/A | -3014.83% | -1589.49% | -1032.64% |
| Cosmos Health Inc. (COSM)vs › | $18.04M | -117.98% | -84.94% | -64.05% | -76.29% |
| BioCardia, Inc. (BCDA)vs › | $15.63M | -271.81% | -934.34% | -347.56% | -265.02% |
ROE
-34.5%
ROA
-30.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -34.50% |
| 2026-03-31 | -47.13% |
| 2025-12-31 | 1.18% |
| 2025-09-30 | 8.65% |
| 2025-06-30 | 178.66% |
| 2025-03-31 | 157.41% |
| 2022-09-30 | -958.21% |
| 2022-06-30 | -326.88% |
| 2022-03-31 | -125.81% |
| 2021-12-31 | -81.64% |
| 2021-09-30 | -120.07% |
| 2021-06-30 | -81.78% |
| 2021-03-31 | -58.13% |
| 2018-09-30 | -280.97% |
| 2018-06-30 | -184.26% |
| 2016-09-30 | -408.42% |
| 2016-06-30 | -119.34% |
| 2015-12-31 | -280.26% |
